Skip to content

Study · Non-randomized trial · n = 8 · 2002

11 results

Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.

Buclin T, Cosma Rochat M, Burckhardt P, Azria M, Attinger M

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 2002Cited by 57 (Europe PMC)

PMID12162502 (opens in a new tab)DOI10.1359/jbmr.2002.17.8.1478 (opens in a new tab)PepBankPUB-12162502
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, oral salmon calcitonin with a caprylic acid derivative carrier had absolute bioavailability of 0.5-1.4%, depending on dose.

    In plain wordsIn healthy volunteers, oral salmon calcitonin with a caprylic acid derivative carrier had absolute bioavailability of 0.5-1.4%, depending on dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableAbsolute oral bioavailability
    Study

    n = 8

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Measurements

    Absolute bioavailability
    0.5 to 1.4%
    oral formulation

    Source sentences

    Summary
    SCT was reliably absorbed from the oral formulation, with an absolute bioavailability of 0.5-1.4%, depending on the dose.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, oral salmon calcitonin decreased blood calcium.

    In plain wordsIn healthy volunteers, oral salmon calcitonin decreased blood calcium.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBlood calcium
    Study

    n = 8

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, oral salmon calcitonin decreased blood phosphate.

    In plain wordsIn healthy volunteers, oral salmon calcitonin decreased blood phosphate.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBlood phosphate
    Study

    n = 8

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  4. 04HumanNon-randomized trialMechanism

    In healthy volunteers, oral salmon calcitonin increased circulating PTH.

    In plain wordsIn healthy volunteers, oral salmon calcitonin increased circulating parathyroid hormone.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseCirculating PTH
    Study

    n = 8

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, oral salmon calcitonin transiently increased urinary calcium excretion.

    In plain wordsIn healthy volunteers, oral salmon calcitonin temporarily increased calcium excretion in urine.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseUrinary calcium excretion
    Study

    n = 8

    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  6. 06HumanNon-randomized trialSafety outcome

    Some healthy volunteers who received oral salmon calcitonin experienced mild, transient nausea.

    In plain wordsSome healthy volunteers who received oral salmon calcitonin had mild, temporary nausea.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableNausea
    Study

    n = 8

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  7. 07HumanNon-randomized trialSafety outcome

    Some healthy volunteers who received oral salmon calcitonin experienced mild, transient abdominal cramps.

    In plain wordsSome healthy volunteers who received oral salmon calcitonin had mild, temporary abdominal cramps.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableAbdominal cramps
    Study

    n = 8

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  8. 08HumanNon-randomized trialSafety outcome

    Some healthy volunteers who received oral salmon calcitonin experienced mild, transient diarrheic stools.

    In plain wordsSome healthy volunteers who received oral salmon calcitonin had mild, temporary diarrhoea.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableDiarrheic stools
    Study

    n = 8

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.
  9. 09HumanNon-randomized trialSafety outcome

    Some healthy volunteers who received oral salmon calcitonin experienced mild, transient headaches.

    In plain wordsSome healthy volunteers who received oral salmon calcitonin had mild, temporary headaches.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableHeadaches
    Study

    n = 8

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    400, 800, and 1200 microg · oral · Single doseAs given in this study (human).

    Source sentences

    Summary
    It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.

Studies that did not test the peptide alone2

In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Calcitonin-salmon.

  1. 10HumanNot a test of Calcitonin-salmon aloneRandomized controlled trialEfficacy outcome

    Oral salmon calcitonin with a caprylic acid derivative carrier reduced blood CTX dose-dependently in volunteers, with 1200 microg exceeding 10 microg intravenously.

    In plain wordsOral salmon calcitonin with a caprylic acid derivative carrier reduced blood CTX dose-dependently in volunteers, with 1200 microg exceeding 10 microg intravenously.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBlood CTX
    Study

    n = 8

    Comparator
    10 microg intravenous salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    It induced a marked, dose-dependent drop in blood and urine C-terminal telopeptide of type I collagen (CTX), a sensitive and specific bone resorption marker, with the effects of 1200 microg exceeding those of 10 microg intravenously.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.

    In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Calcitonin-salmon.

  2. 11HumanNot a test of Calcitonin-salmon aloneRandomized controlled trialEfficacy outcome

    Oral salmon calcitonin with a caprylic acid derivative carrier reduced urine CTX dose-dependently in volunteers, with 1200 microg exceeding 10 microg intravenously.

    In plain wordsOral salmon calcitonin with a caprylic acid derivative carrier reduced urine CTX dose-dependently in volunteers, with 1200 microg exceeding 10 microg intravenously.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrine CTX
    Study

    n = 8

    Comparator
    10 microg intravenous salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    It induced a marked, dose-dependent drop in blood and urine C-terminal telopeptide of type I collagen (CTX), a sensitive and specific bone resorption marker, with the effects of 1200 microg exceeding those of 10 microg intravenously.
    2 context sentences
    Summary · context
    In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier.
    Summary · context
    Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion.

    In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Calcitonin-salmon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.